We are live on
!
Find out more
TA
Tamarack Advisers Portfolio holdings
AUM
$2.12M
1-Year Est. Return
58.09%
This Fund
S&P 500
This Quarter
Est. Return
+21.92%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$171M
AUM Growth
+$11.3M
(+7%)
Cap. Flow
-$9.27M
Cap. Flow
% of AUM
-5.41%
Top 10 Holdings %
Top 10 Hldgs %
62.79%
Holding
42
New
12
Increased
7
Reduced
13
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
TVTY
Tivity Health, Inc. Common Stock
TVTY
|
+$5.19M |
| 2 |
Dentsply Sirona
XRAY
|
+$4.86M |
| 3 |
Medtronic
MDT
|
+$3.79M |
| 4 |
MDRX
Veradigm Inc. Common Stock
MDRX
|
+$3.46M |
| 5 |
Labcorp
LH
|
+$2.85M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teladoc Health
TDOC
|
+$7.63M |
| 2 |
Boston Scientific
BSX
|
+$5.31M |
| 3 |
ATHN
Athenahealth, Inc.
ATHN
|
+$3.38M |
| 4 |
WBA
Walgreens Boots Alliance
WBA
|
+$3.29M |
| 5 |
Alkermes
ALKS
|
+$2.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94.86% |
| 2 | Industrials | 3.22% |
| 3 | Consumer Discretionary | 1.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MDRX
1
DELISTED
Veradigm Inc. Common Stock
MDRX
| $15.9M | 9.31% |
1,250,000
+285,000
| +30% | +$3.46M |
|
2
NovoCure
NVCR
$1.73B
| $15.7M | 9.14% |
905,000
-85,750
| -9% | -$1.11M |
|
3
Nektar Therapeutics
NKTR
$2.39B
| $11.5M | 6.73% |
39,333
+6,000
| +18% | +$1.73M |
|
|
4
Labcorp
LH
$25B
| $10.5M | 6.12% |
79,152
+23,280
| +42% | +$2.85M |
|
5
Pacira BioSciences
PCRX
$1.04B
| $10.3M | 5.99% |
215,000
-50,000
| -19% | -$2.32M |
|
|
SPNC
6
DELISTED
Spectranetics Corp
SPNC
| $10.2M | 5.94% |
265,000
-35,000
| -12% | -$1.01M |
|
7
Gilead Sciences
GILD
$162B
| $9.55M | 5.58% |
135,000
-15,000
| -10% | -$998K |
|
8
Jazz Pharmaceuticals
JAZZ
$15.9B
| $8.55M | 4.99% |
55,000
-2,000
| -4% | -$306K |
|
|
CORV
9
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
| $8.14M | 4.75% |
1,800,000
-25,000
| -1% | -$90.7K |
|
|
CORI
10
DELISTED
Corium International, Inc.
CORI
| $7.27M | 4.25% |
975,000
-88,000
| -8% | -$523K |
|
11
Steris
STE
$22.3B
| $6.93M | 4.04% |
85,000
-13,150
| -13% | -$1,000K |
|
12
Lantheus
LNTH
$6.49B
| $6.79M | 3.97% |
385,000
+94,300
| +32% | +$1.39M |
|
|
TVTY
13
DELISTED
Tivity Health, Inc. Common Stock
TVTY
| $6.18M | 3.61% |
+155,215
| New | +$5.19M |
|
|
HIND
14
Vyome Holdings
HIND
$14.9M
| – | – |
0
| – | – |
|
|
15
Dentsply Sirona
XRAY
$2.68B
| $4.99M | 2.91% |
+77,000
| New | +$4.86M |
|
16
Brookdale Senior Living
BKD
$3.49B
| $4.78M | 2.79% |
325,000
-178,000
| -35% | -$2.46M |
|
|
SRCL
17
DELISTED
Stericycle Inc
SRCL
| $4.58M | 2.67% |
60,000
+30,200
| +101% | +$2.48M |
|
18
HCA Healthcare
HCA
$87.2B
| $4.36M | 2.55% |
50,000
-30,000
| -38% | -$2.54M |
|
|
19
Medtronic
MDT
$109B
| $3.99M | 2.33% |
+45,000
| New | +$3.79M |
|
|
WBA
20
DELISTED
Walgreens Boots Alliance
WBA
| $3.92M | 2.29% |
50,000
-40,000
| -44% | -$3.29M |
|
|
NXTM
21
DELISTED
NxStage Medical Inc.
NXTM
| $3.2M | 1.87% |
127,500
+17,500
| +16% | +$433K |
|
22
Service Corp International
SCI
$11.7B
| $1.84M | 1.07% |
+55,000
| New | +$1.75M |
|
|
23
Alkermes
ALKS
$8.22B
| $1.74M | 1.02% |
30,000
-50,000
| -63% | -$2.9M |
|
|
ISEE
24
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $1.6M | 0.93% |
625,000
+153,851
| +33% | +$419K |
|
|
STRM
25
DELISTED
Streamline Health Solutions
STRM
| $1.22M | 0.71% |
75,867
| – | – |
|
Similar funds
SCM
LBC
ICM
LCMP
GIP
STC
GC
DU
Tamarack Advisers's Q2 2017 Portfolio in Review
As of Q2 2017, Tamarack Advisers held 42 positions worth $171M, up 7% from $160M the previous quarter. Its ten largest holdings account for 63% of the portfolio.
Tamarack Advisers withdrew a net $9.27M in Q2 2017, closing 8 positions and reducing 13 holdings. Its most notable exit was Teladoc Health, an estimated $7.63M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Industrials and Consumer Discretionary.
Against the trend, Tamarack Advisers opened a new position in Tivity Health, Inc. Common Stock worth $6.18M.
- Tamarack Advisers's largest Q2 2017 buy was Tivity Health, Inc. Common Stock: 155,215 shares worth $6.18M.
- Tamarack Advisers added most to Veradigm Inc. Common Stock in Q2 2017, an estimated $3.46M increase.
- Tamarack Advisers's biggest Q2 2017 reduction was Walgreens Boots Alliance, cutting an estimated $3.29M.
- Tamarack Advisers fully exited Teladoc Health in Q2 2017, selling an estimated $7.63M.
- Tamarack Advisers's ten largest holdings make up 63% of its $171M portfolio in Q2 2017.
- Tamarack Advisers opened 12 new positions and closed 8 in Q2 2017.
- Tamarack Advisers's portfolio value rose 7% quarter-over-quarter to $171M.
Based on Tamarack Advisers's 13F filing for Q2 2017, filed 8 Aug 2017.